Claims

1. A pharmaceutical composition, comprising:

   (a) a first agent being an agent that possesses anti-inflammatory activity, said agent being selected from the group consisting selected from aspirin, celecoxib, indomethacin, nimesulide, piroxicam and diclofenac;
   (b) a second agent being an AMPK activator, said AMPK activator being selected from the group consisting of metformin, phenformin or buformin; and
   (c) a third agent that possesses or maintains serotonin activity, said agent being serotonin creatinine sulfate complex.

2. The composition of claim 1, wherein the composition consists of 1-5000 mg of the first agent, 5-5000 mg of the second agent, and 0.1-1000 mg of the third agent.

3. The composition of claim 1, wherein the composition consists of 1-5000 mg of the first agent, 5-5000 mg of the second agent, and 0.1-1000 mg of the third agent and a pharmaceutically acceptable carrier.

4. The composition of claim 1, wherein the first agent is celecoxib.

5. The composition of claim 1, wherein the first agent is aspirin.

6. The composition of claim 1, wherein the composition contains metformin hydrochloride, aspirin, and a serotonin creatinine sulfate complex.

7. The composition of claim 1, wherein the composition contains metformin hydrochloride, celecoxib, and a serotonin creatinine sulfate complex.

8. The use of the composition according to any one of claims 1 to 7, in the manufacture of a medicament for treatment of a hyperproliferative disease.

9. The use according to claim 8, wherein the hyperproliferative disease is a malignant tumor.

10. The use according to claim 9, wherein the hyperproliferative disease is a solid tumor.